Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Hemorrhage 13Neoplasms 7Leiomyoma 6Breast Neoplasms 6Hematologic Neoplasms 4Thrombocytopenia 3Postoperative Hemorrhage 3Meningioma 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Seroma 2Prostatic Neoplasms 2Ovarian Neoplasms 2Myofibroma 2Head and Neck Neoplasms 2Colonic Neoplasms 2Brain Neoplasms 2Bone Neoplasms 2Blood Loss, Surgical 2Wrist Fractures 1Urologic Diseases 1Urinary Retention 1Thromboembolism 1Skin Neoplasms 1Seizures 1Sarcoma 1Recurrence 1Postoperative Complications 1Polyposis, Gastric 1Pituitary Neoplasms 1

Interventions

pasireotide 7Cabergoline 7Temozolomide 3Propofol 3Hydrocortisone 3Dexmedetomidine 3lanreotide 2Sevoflurane 2Saline Solution 2Rosiglitazone 2Proton Therapy 2Octreotide 2Dexamethasone 2Desflurane 2pegvisomant 1parecoxib 1lutetium Lu 177 dotatate 1loxoprofen 1farletuzumab 1entinostat 1corticorelin ovine 1antineoplaston AS 2-1 1antineoplaston A10 1Yoga 1Trimethoprim 1Transcranial Magnetic Stimulation 1Tranexamic Acid 1Tramadol 1Thyrotropin-Releasing Hormone 1TBR-760 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pituitary Neoplasms × Tranexamic Acid × Clear all
NCT04863339 2022-04-05

Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery

University of North Carolina, Chapel Hill

Phase 2 Withdrawn
Endocrine

Hemorrhage, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡